Neurocrine (NBIX) Director Shalini Sharp Receives RSU Award

What Happened Shalini Sharp, a director of Neurocrine Biosciences (NBIX), was granted 2,567 restricted stock units (RSUs) on May 27, 2026. The Form 4 reports the RSUs as an award/derivative acquisition (code A) at $0.00 per unit (total reported value $0.00), meaning no cash purchase was made — these are a compensation/award grant that converts to shares upon vesting.

Key Details

• Transaction date: May 27, 2026; Filed on Form 4: May 29, 2026 (filed within the usual two-business-day window).
• Grant: 2,567 RSUs @ $0.00 (derivative award); total reported value $0.00.
• Vesting: RSUs vest in full on May 27, 2027 (see footnote).
• Shares owned after transaction: Not stated in this Form 4.
• Footnotes: F1 clarifies each RSU equals the right to one share upon vesting; F2 states full vesting date (May 27, 2027).
• No 10b5-1 plan, tax withholding event, or late-filing indication is included in the filing.

Context This was an equity award (compensation) rather than an open-market purchase or sale. For retail investors, awards signal how the company compensates insiders but do not necessarily indicate immediate bullish or bearish trading by the insider — the RSUs will only convert to shares if/when they vest.